Stereotactic body radiotherapy with CyberKnife® System for low- and intermediate-risk prostate cancer: clinical outcomes and toxicities of CyPro Trial

Simple summaryStereotactic body radiotherapy (SBRT) of 35–36.25 Gy in five fractions with the CyberKnife System yields excellent control with low toxicity in low–intermediate-risk prostate cancer patients. We found no differences in biochemical control and overall survival in relation to dose. There...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Valentina Borzillo, Esmeralda Scipilliti, Donato Pezzulla, Marcello Serra, Gianluca Ametrano, Giuseppe Quarto, Sisto Perdonà, Sabrina Rossetti, Sandro Pignata, Anna Crispo, Piergiacomo Di Gennaro, Valentina D’Alesio, Cecilia Arrichiello, Francesca Buonanno, Simona Mercogliano, Antonio Russo, Antonio Tufano, Rossella Di Franco, Paolo Muto
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2023-11-01
Edice:	Frontiers in Oncology
Témata:	clinical outcome toxicity low-and intermediate-risk radiotherapy prostate cancer stereotactic body radiation
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1270498/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!